This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop selective small molecule inhibitors against the CYP8B1 enzyme as a novel approach to treat hepatocellular carcinoma (HCC), including metabolic dysfunction-associated HCC. The $793,324 award to the Beckman Research Institute of the City of Hope will fund the following key activities over the project period from April 2025 to March 2028: High-throughput screening of the...
This Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to improve understanding and treatment of hepatocellular carcinoma (HCC), a prevalent and aggressive form of liver cancer. The $687,679 grant, awarded on December 15, 2024, will fund a multidimensional research plan led by a team at Columbia University's Health Sciences Division. The key objectives of the research are to: 1) computationally...
This is a Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) to the Sanford Burnham Prebys Medical Discovery Institute. The $2,397,277 award, with a performance period from September 2024 to August 2029, supports research to investigate the mechanisms by which metabolic stress and mitochondrial dysfunction contribute to the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC), the most common type of primary...
The National Cancer Institute (NCI) has awarded a 5-year, $599,299 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the University of Illinois in Chicago. The goal of this research project is to further validate the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and its impact on the development of non-alcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC). The researchers will employ a mouse model of NASH-induced HCC to study how HK2 regulates...
The National Cancer Institute (NCI) awarded a $483,591 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, Davis (UC Davis) with an effective date of August 1, 2024 and a planned completion by July 31, 2029. The grant supports research to design, clone, express, and purify novel "bioengineered RNA" (bioRNA) molecules that can target and modulate the metabolism of hepatocellular carcinoma (HCC), the most common form of liver cancer....
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $1,224,644 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at understanding the role of the B7-H4 protein and its interaction with the TGF-beta pathway in intrahepatic cholangiocarcinoma (CCA), a rare and deadly form of liver cancer. The key objectives are to: 1) Elucidate the molecular mechanisms by which B7-H4 promotes CCA cell growth, motility, and...
This Project Grant award of $284,556.32 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at the Sloan-Kettering Institute for Cancer Research to investigate the crosstalk between obesity-induced fatty liver disease and liver metastasis. The research aims to elucidate how cancer mechanistically takes advantage of the lipid-rich and inflammatory environment of non-alcoholic fatty liver disease (NAFLD) to promote liver metastasis, particularly in the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research into the role of the urea cycle enzymes (UCEs) in the development and progression of hepatocellular carcinoma (HCC), the primary type of liver cancer. The $450,997 award to Rutgers, The State University of New Jersey aims to: 1) determine if suppression of UCE expression contributes to HCC growth driven by oncogenic β-catenin; 2) study how β-catenin regulates UCE transcription;...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to decipher the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a highly lethal form of liver cancer. The $518,219 award, effective from April 4, 2025 to March 31, 2030, will support research at the University of Pittsburgh to investigate how the activation of the FXR and CAR nuclear receptors in the context of cholestatic liver diseases, such as primary...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $165,883 to support Dr. Xinyuan (Cindy) Zhang's research at Brigham & Women's Hospital to investigate the role of inflammation in the development of hepatocellular carcinoma (HCC). The key objectives of the research project are to: 1) Examine pre-diagnostic plasma proteomics of HCC cases versus controls to develop and validate inflammatory proteomics signatures for early...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) in the amount of $213,284 supports research to develop novel CYP8B1 inhibitors for the treatment of obesity-associated hepatocellular carcinoma (HCC). The awardee, Beckman Research Institute of the City of Hope, aims to determine the role of CYP8B1 in obesity-associated HCC and create more potent and selective CYP8B1 inhibitors. The project involves conducting studies in obesity-associated HCC mouse models to evaluate the impact of CYP8B1 knockout and novel CYP8B1 inhibitor treatment on HCC growth. The research also includes further chemical optimization to develop lead CYP8B1 inhibitor candidates with improved potency, selectivity, and efficacy. This work is expected to advance the understanding of CYP8B1's role in obesity-associated HCC and produce potential new therapeutic approaches to treat this condition.